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INTRODUCTION 
A fact or two about hypertension is enough to make 
apparent the reason there have been numerous attempts~ futile 
though many have seemed~ to arrive at sane cure~ some treat-
ment, for high blood pressure. over 5001 000 people a year 
die of cardiovascular-~enal disease1• Hypertension has been 
deemed responsible for over 75% of the casesl. Masterrs2 
states that 41% of the male populatiion and 51% of the female 
population of the United States over forty years of age have 
a blood pressure of 150/90 or higher. We see~ thus, that the 
majority of patients who lose their lives by way of a cerebral 
hemorrhage~ coronary thrombosis~ or he~failure~ because of 
a cardiovascular-renal disease as a consequence of hyperten-
sion, are in an age group including some of the most dynamic, 
capable, and productive members of our society. Certainly 
any method that shows indications leading to the preservation 
and prolongation of their lives~ and many others~ is worthy 
of investigation and trial. 
Through the years~ as a result of organized correlation 
between clinical and experimental work, many advances have 
been made in our knowledge of the etiology and treatment of 
hypertension. The constantly fluctuating status of the manage-
ment of hypertension, that new evidence perpetuates~ can be 
recognized by reviewing papers written over a period of time 
I 
:cqncerning the topic. 0'Hare3 (1927)~ Weiss4~5 (1930), 
I 
0 
Mosenthal5 (1940), Hamburger7 (1941), and Goldring8 (1943) in 
1 
their respective presentations of the subject in the last 
I 
twenty years show this effect clearly. Because of these new 
1\ investigative achievements and continual revision of concepts, 
\, the clinicain of today has at his disposal several surgical 
and medical procedures for the treatment of hypertension. 
The medical treatment divides itself into psychic, dietar~ 
1 organotherapeutic, and pharmacological procedures. The surgical 
teohniques are those dealing with extirpation of tumors, removal 
of obstructions, severing the splanchnic nerves, or complete 
sympathectomy. It is obvious that the physician must use all 
this knowledge to the utmost in dealing with his patient 
troubled by the clinical symptom of high blood pressure. This 
necessitates a scrupulous study of the history, physical examina-
tion, and laboratory work done on the case to establish the 
\itiology of the hypertension. 
II After having determined the etiology, if possible, the 
~rocedure indicated by the workup should be employed. If our 
- II ~roblem is not within the surgical realm, then medical treatment 
ls in orde;. Of course, rest, relief from worry and tension, 
~ietary measures (principally reduction in weight), and dealing 
tith the patient and his problems psychosomatically, are methods 
lried and true, but alone they stand to be defeated. What 
iedical supports may we avail ourselves of in addition to these? 
\ . The two most recent, and both presumably directed toward 
I 
I the initiating mechanism of hypertension, are, firstly the one 
II 
utilizing the antipressor effect of renal extracts9, and 
secondly, the technique aiding the completion of the process 
~ of de·amination by the kidney10., both of which are still in the. 
experimental stage, in that enough clinical evidence as to 
their efficacy has not been gathered.e Goldring8, in 1943 
attempted confirmation of the o~~ginal results of these studies 
and observed that pyrogenic reactions obsc~ed any specific 
antipressor effect which may have been present. He concluded 
[that for a final estimate of their respective values it would 
be necessary to produce an extract free of impurities and to 
run trials on large series of hypertensive humans. 
The sedatives, vasodilators, and empiric remedies avail-
able have been found of little value by some clinicians6,7,8; 
others,ll, 12, 13, feel differently. Of the empiric remedies 
used in the treatment of hypertension, the one that pops up 
continually, like a bad penny, and creates controversy inces-
santly, is thiocyanate. For this reason let us delve into tbe 
problem of tpiocyan~te in the treatment of high blood pressure 
and see what its appliance in the past 43 years has yielded. 
Our plan of attack includes a review of thiocyanate's 
pharmacology, as it pertains to its use in hypertension, a 
consideration of the therapeutics evolved since the drug's 
initial administration, terminating with an attempt to evaluate 
the usefulness of thiocyanate, as a remedial agent for high 
11blood pressure, from the clinical reports studied. 
II 
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PHARMACOLOGY 
l. CHEMISTRyl-4 
HONS, sul~ocyanic acid, is an unstable substance easily 
decomposed by boiling or exposure to air; but it ~orms a large 
number o~ stable alkaline salts, namely, sodium, potassium, 
and ammonium t4mocyanate. These solutions react with a drop or 
I two of FeOl in acid solution to give a brilliant dark red color 
: which disappears on the addition o~ an axcess or Hg012• This 
I 
test has a sensitivity o~ about 1-lo,ooo. The sodium, potassiun, 
~d ammonium salts are white crystalline substances, very 
soluble in water and alcohol, possessing a salty taste, and are 
'1 the ones employed in the therapy under discussion. 
Thiocyanate is ~ound normally as part o~ saliva in con-
centrations o~ .Ol%. It can be ~ound in othe~ secretions and 
body :fluids, e.g. tears and gastric juice. The or~gin of this 
compound is generally supposed to be a resultant o~ the kata-
bolism o~ sul~ur-containing proteins and is ~ormed mainly by 
!the salivary glands, swallowed, and absorbed into the system. 
jl The ~erric salts o~ HONS produce a red substance used by 
I[ German investigators and called "rhodanate". 
2. ABSORPTION, DISTRIBUTIIDN, FATE, AND EXCRETION. 
A. Absorption. 
The thiocyantes are readily absorbed f.rom the gastro 
intestinal tract15. 
B. Distribution. 
In a series o~ three studies pertaining to the distri-
l. 
bution of iodide, thiocyanate, bromide and chloride in the cen-
tral nervous system and spinal fluid, done by Wallace et a1. 16, 
I<=) it was found that thiocyanate is distributed almost exclusively 
' t fit) ( 
0 
·I, 
1: 
li 
' in extra cellular fluid, the relationship remaining unchanged i 
pathological tissue. Furthermore, iodide, thiocyanate, bromide 
and chloride are distributed in the extracellular water of the 
central nervous system in ionic equilibrium with the spinal 
fluid, whereas in all other tissues of the body it is found to 
be in equilibrium with the serum. 
Recent work infers. that there is a lag in the diffu-
sion of thiocyanates into edema fluid and transudates; thus the 
concentration in these fluids will not be as great as that 
found in plasma17. 
The tissue cells are apparently impermeable to the 
' ion1.5. 
C. Fate 
The thiocyanate ion does not dissociate further in 
the bodyl.5 '· the atomic linkage being s-c:N; and it has no 
actions in common with cyanide1.5. In fact, cyanides are detoxi· 
fied in our bodies by conversion to the more stable relatively 
innocuous thiocyanate18 • 
D. Excretion 
Thiocyanate is found normally in the bodyl4; however, 
when present as a result of willful ingestion and absorption, 
the principal excretory route is via the kidney. Laugl9, '(1936) 
demonstrated that thiocyanate is actively secreted by the kidne 
2. 
0 
the Kidney is one of removal of a w~thless metabolic end 
product. 
Goldring and Chasis20,(l932,CHART I}, in a trial 
conducted with seven patients, four nephritics, one normal and 
two essential hypertensives, presented evidence to show that 
the ease with Which thiocyanate is excreted bears a direct 
relation to the efficiency of the kidney; and secondly, the) 
average daily dosage was not correlated with the amount excrete< 
per day. 
CHART I 
A COMPARISON OF THE EXCRETION RATE OF THIO-
CYANATE IN ESSENTIAL HYPERTENSION AND NEPHRITIC HYPERTENSION 
NO. TYPE OF 
HYPERTENSION 
1. Nephritic-lHt-
2. Nephritic 
3. Nephritic 
4. Essential 
5. Essential 
1 .. Normal 
2. Nephritic 
AVERAGE DAILY DOSE AVERAGE THIOCYANATE EXCRETI01 
GM. GM. PER 24 HRS. 
0.978 0.097 
1.004 0.227 
0.652 0.250 
0.978 0.450 
0.915 0.557 
1.143 (single dose} 
1.143 (single dose} 0.088 0.043 
*After Goldring and Chasis20 
**Chronic diffuse glomerulonephritis 
Wa1d and associates21,( 1939,CHAR~ II}, pointed out a 
. "wide individual variation in renal th~acyanate clearance, the 
[Jlack of relationship between blood thiocyanate level and thio-
\ cyanate clearance, and the marked difference existing betweren 
0 thiocyanate and renal urea clearance", employing the blood 
level device introduced by Barker22 in 1936. These experiments 
1 were confirmed by Koffler23 in 1944. 
II 
II 
II . 
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CHART II 
1 THE WIDE INDIVIDUAL VARIATION IN RENAL THIOCYANATE CLEARANCE, 
, THE'. LACK OF RELATION SHIP BETWEEN BLOOD THIOCYANATE LEVEL AND 
THIOCYANATE CLEARANCE, AND THE MARKED DIFFERENCE EXISTING 
BETWEEN THIOCYANATE AND RENAL UREA CLEARANCE* 
I CASE SEX AGE TYPE OF CASE UREA, THIOCYANATE THIOCYANATE 
CLEARANCE CLEARANCE 0~ BLOOD LEVEL 
PERCENT PER MINUTE MGM P~CENT 
J. M Normal 85 3.50 5.70 
2 F Normal 77 1.9 3.80 
3 M Superhypertension 108 0.62 4.70 
-4 F Hypertension, 44 0.32 5.20 
cardiac decomp~n-
sation 
5 ¥ Chronic nephritis, 31 0.31 17.1 
advanced 
6 M Chronic nephritis, 5.5 0.62 11.4 
advanced 
'7 M Hypertension 72 0.32 le.2 
, *It will be noted, however, that although urea clearance 
! may be accompanied by a low thiocyanate clearance, tlie latter 
is consistently low when the urea cle.arance is low. 
Chart after Wald, Lindberg, and Barker21. 
Nelsonl8 states that "the excretion of thiocyanate 
depends on the efficiency of circulation, water balance, and 
the integrity.of the kidney". 
3. TOLERANCE 
A tolerance to· thiocyanate does not seem to existll. 
4. DOS.AGE AND TECHNIQUE OF ADMINISTRATION 
The proper dosage of thiocyanate needed to obtain the 
desired clinical results without incurring toxic symptoms, the 
' . 
most severe ~ which is toxic psychosis c~lminating in death, 
0 has been a bone of contention throughout the history of its 
application in the treatment of hypertension; and rightly so~ 
. 
jfor it is a dangerous drug whan not administered·cautmo~sly. 
I 
4. 
II 
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I 
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interest in thiocyanate's use as a remedial agent in the treat-
ment of hypertension lagged. On the strength of these latter 
40 results the J.A.M.A. , in 1934, reported that thiocyanates in 
(:) small doses were inadequate to lower blood pressure and large 
amounts were toxic; therefore, it was not a drug that could be 
accepted by the Council on Pharmacy and Chemistry of the 
() 
I.__/ 
' American Medical Association. 
The period just described may be identified as the pre-
1 Barker era of the use of thiocyanate in the treatment of high 
blood pressure. Barker22 , after becoming gernerally dissatis-
fied with results obtained using a nhit and miss" method of 
estamating proper dosage of thiocyanate intoduced a modificatioi 
of Schrieberts41 method of determing serum levels of thiocyanatE 
to suit his own needs. His studies revealed that the hypotensiie 
action and subjective relief obtained on a series of 35 hype~­
tensive patients correlated with the blood level of thiocyanate 
in the serum. He concluded that the optimum therapeutic level 
was between 8-12 mgm. per 100 cubic centimeters of blood and 
that significant toxicity appeared at levels from 15-30 mgm. 
pe.r 100 cubic centimeters of blood serum. He stated further 
that levels can increase with remarkable rapidity in certain 
individuals, so that the use of thiocyanate is safe only if 
patients are watched carefully and drug levels are cautiously 
con trolled. 
Barker's work stimulated a new enthusiasm in this phase 
of hypertension therapy. Approximately twenty-eight (Chart VII 
investigators have tried the new method of thiocyanate control 
after its introduction and have been satisfied that thiocyanate 
could be used successfully with prudence. The six latest con-
~ributions, by Massie42 (1941), Durant43 (1944), Bynum44 (1941) 
!pavinessll (1942), and Del Solar45 (1945} tend tp advocate the 
I' ~aintenance of blood levels as low as possible within the 
1: 
6. 
I 
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I 
0 
~ 'therapeutically effective range. A blood serum level of betweei 
5-? mgm. per 100 cubicoentimeters and seldom above 9 mgm. per 
100 centimeters is what they prefer. 
As regards dosage, Barker22 advocated .3 gms. in either 
' liquid or tablet form for four to six weeks with weekly visits.· 
At each visit a blood concentration would be done and dosage 
I varied as indicated. The dosage is decreased if there is a 
sharp fall in blood pressure or if symptoms of fatigue and 
depression are great enough to interfere with the patient's 
\ sense of well-being. The dosage may be doubled during the 
• 
second or third week if the blood concentration does not reach 
a level of 6 mgm. percent, and if there has been no blood 
pressure change nor untoward toxic symptom. Throughout the 
whole course of cyanate therapy it will be found necessary to 
vary the dosage, either increased, decreased, or temporavily 
discontinued depending on the patient's symptoms, blood pressurE, 
and blood level concentration. Barker emphasizes fastidious 
care in the treatment of the patient. He adds that symptoms of 
fatigue, somnolence, and mental retardation are often observed 
during the first four weeks of administration, but soon disa-
ppear; therefore they are not, as a rule, indications for 
discontinuing therapy, although dosage may be modified. 
l Koffler23 in one of the more recent articles on treatmen~ 
\ 
ith thiocyanate, proposes essentially the same method. He 
recommends giving .1 gm. three times a day for one week and 
~equests that the patient return for a blood level at the end 
of that wee~. Using the same indications Barker22 employed, 
KOffler varies his dosage accordingly. He emphasizes the point 
I:O that .1 gm. daily may in certain oases be capable of maintain-~~ 
0 
.i; ing a therapeutic level. 
0 
" 
In the pre-Barker (1903-1935) era, Egloff29 reported 2 
successes out of 25, stating that "every patient complained of 
one or more distressing symptoms arising from 2-8 days after 
the drug was commenced". Their patients received 1 gm. daily 
for one week, followed by .6 gm. daily f.or the second week, 
and ·3 gm. daily the third week. With our present knowledge of 
proper dosage, it seems that their difficulty can be accounted 
for. 
Conoensus of opinion,.Barker46, Massie47, Kurtz48, Bynun44 
and Durant43, places the average maintenance level between .2-
1
.4 gm. daily, however, being aware that vast individual varia-
1\tions exist among patients. 
I The minimal lethal dose for man has been estimated by 
Nicholsl4, from his experimental work with guinea p~gs, to be 
·~5-30 gms. for a man weighing 70 kg. 
~~. METHOD FOR DETERMINATION OF SERUM LEVEL 
The method elaborated by Barker22 in 1936 was a modifioa-
l
iion of Schrieber•s4l original technique, and is tully describ-
ed in his paper. In 1937 Griffith53 developed a new micro-
kethod for determination of blood thiooyanates, initiating the 
lse of ink standards and the use of blood taken from the finger 
II ~ather than venous blood. Griffith's technique is completely 
II 
a. 
I• 
outlined in his study, and results obtained with it correlate 
well with those derived when using Barker's mode of determinati«•n. 
1:0 Ginsburg.54 (1939, employed and advocated the application 
~ I 
1: 
\I 
1: 
I! 
I; 
[I 
,I 
b 
" 
of a photoelectric colorimeter to determine the amount of thio-
cyanate directly on the serum, obviating the necessity of pre-
oipating protein that the other routines required. It facili-
tates the measurement and yet maintains the accuracy of 
Barker's method. Therefore, of all the techniques proposed, it 
has been the one adopted by most large clinical laboratories 
that undertake this determination. Tuokerwiller.5.5 reports 
that a twelve co. mailing tube, filled with blood, being carefw 
to avoid hemolysis, ca~ be used to send specimens on which 
thiocyanate levels are desired to nearly laboratories. 
Ravin56 has originated permanent standars which may be 
used for oompaJ;'ison, eliminating the time consuming proce·ss of 
!preparing fresh standards every day. 
I ~ Norris, Martin and Sunderman57 , noted the overlapping of 
1oolor development in the analysis of blood serum containing 
both salioylates and thiooyanates, and devised a method for 
measuring both when together, which they describe in their papeJ • 
Eli Lilly44 manufactures a kit for doing blood cyanate 
\estimations, selling for three dollars, that can be utilized 
~Y the busy practitioner; for it takes but 8 - 10 minutes to 
II k d. ma e a rea J.ng. l MECHANISM BYlWHICH THIOCYANATE PRODUCES ITS HYPOTENSIVE EFFE<1 T 
I • 
II 
'·'Probably there is- no product of metabolic activity of 
) 
which there is more doubt as to the origin and systemic action 
than potassium sulphocyanate" is a statement made by Lodholz71 
introducing his paper, written in 1905, relating to the systemi1 
action of sylphocyanate. Since that time more researchers have 
been active and a number of plausable hypotheses have been post· 
ulated as to the hypotensive activity of thiocyanate. Let us 
~eview some of the more substantial ones. 
Stimulated by the favorable effects Cavinessll obtained 
in his treatment of 87 ambulatory hypertensive patients, he 
decided to investigate the correlation between the blood 
press~e and thiocyanate concentration in untreated cases. In 
194158, (CHART III), he studied 242 subjects and found that 
leach individual had a fixed thiocyanate level that does not 
~luctuate from week to week. He found the level varied among 
individuals from .31 to 2.55 mgms. per 100 cc. of blood with 
an average of 1.238 mgms. per 100 cc. He discovered next that 
~he average blood sulphocyanate level for each blood pressure 
group varies inversely with the blood pressure. This led to 
rhe postulate59 that •there exists a delicate balanCe of con~ 
lrol between some complex substance secreted by the adrenals 
~orming an active, potent presor substance which normally 
baintains the tone of the arterioles (musculature) and probably 
~t least some of the capillaries and the ~lood cyanates elabora· 
=> red by protein metabOlism". From this might be inferred that 
thiocyanate treatment may be just replacement therapy. 
Recent work, (1944), carried on by Dalton65 seems to 
10. 
lknown that sulphocyanates were used in manufacturing enter-
prises where it is necessary to precipitate iron from certain 
materials; thus Doles concluded this would be a satisfactory 
11. 
manner in which to precipitate the iron stored in the liver 
and spleen. This hypothesis led to the following experiment62 
Ten patients were admitted to the hospital who had hyper-
tension and macrocytosis. 11 T.hey were first given a general 
diet with an intake of 30 mgms. of iron daily through food 
and water. After the fitth day the output of iron per 24 hours 
was estimated in stools and urine. For four days the average 
output was from 14.5 to 16 mgms. ever 24 hours. They were 
then given a diet in which the maximum intake of iron per 24 
hours did not exceed·7.5 mgms• and after the fifth day quanti-
tive estimates were made fo~ 5 days. 0nly a faint trace could 
be found i~ stools and none in the urine. The same procedure 
was carried out continuing this diet and the patient was given 
sodium sulphocyanate* drams 3 twice a dayl From 12.5 to 24.5 
mgms. of iron were recovered in the stools and urine every 
twenty-four hours. So long as the patient showed a relatively 
high output of iron in the stools and urine then there was a 
fall of packed cells and a corresponding fall in blood pressurE • 
T.his experimental evidence enabled Doles to conclude that 
"the mode of action of sulphocyanate seems to be by precipita-
. 
tion of iron". In Dole's work the blood pressure fall may be 
accounted73 for by the decreased blood viscosity as a resultan;, 
of treatment, which diminishes the peripheral resistance. 
*preparation contains 1.33 gm/30 cc. 
12 
b 
Friend and Robinson63 (1938) report, n1. OXygen consump-
tion of rat liver cells is depressed by the thiocyanate ion 
when added to the serum in vitro; and, 2. Serums from patients 
receiving thiocyanate and exhibiting concentrations of the 
drug from 8 to 22 mgms. per 100 co. do not appear to depress 
the oxygen consumption of rat liver cells suspended in them". 
Their experiments intimate that thiocyanates depress the blood 
pressure by reducing the basal metabolic rate of the tissues. 
navis, L. and Barker, H. 64 (1941}, conducted experiments 
on normal dogs, ischemic hypertensive dogs and normal dogs 
1with elevated blood cyanate levels that demonstrate that 
intravenous potassium thiocyanate produces its depressor effect 
as a result of generalized vasodilation. Removal of the 
thoracic sympathetic trunk ~nd the splanchnic nerves supradia-
phragmatically will accentuate the effect of thiocyanate. T.hes 
facts explain Barker and Davis's72 clinical observation that 
patients who respond poorly to sulphocyanate therapy previous 
to bilateral splanchniotomy may become sensitive afterwards. 
~ . 
13 
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CHART III 
AVERAGE OF TEE RESULTS FROM PRISON AND DIX HILL PATIENTS 
No. of' Mgms. KCNS Blood Pressure 
Per 
~~up Percent Weight Heighi ISON Patients Serum Systolic Diastolic Af!.e lbs. in chef 
II · 9 97.8 60.0 ~:potension 1.424 34.9 147.7 6?.6 
or mal 91 1.238 118.0 74.8 28.0 14?.0 67.4 
1d
1
rderline 19 1.071 137.4 76.3* 29.1 1.50.2 67.7 
,pertension 28 0. 90.5 1?6·.0 106.2 41 • .5 1;8.8 67.7 
Jl!X HILL 
~!Po tension 10 1.048 89.9 66.8 33·.5 140.9 67.2 ~~ mal 34 1.106 121.8 79.6 3.5-7 1.53-7 69.0 ~~derline 12 0.8;6 1;9.4 88.2 41.2 160.; 69.2~ 
!Y'];>e.rtens ion ;a 0.904 166.7 99.1 .54.3 1,54.;* 67 .;:~ 
I 
*Average using one less number of' patients 
**Average using two less number of' ~~tients 
Chart taken from Caviness' report • 
~ 
Glaude Bernard66 and earlier investigators believed ~hat the 
s~lf'ocyanates acted as a direct smooth muscle poison and abolisheQ 
nhscular activity without producing any sensory change; a theory 
lng since disproved. Pauli67 and Bentley and LeRoy68 thought 
~le benef'icial effects of thiocyanate could be attributed to 
~leir ability to desolve .calcerous deposits in the arteries. 
~1gefiel2.5 objected to this because of the sudden drop of' blood 
pJessure produced by the drug, and.the fact that it did not last 
Jl . i . . ~fter d1scont nuat1on of 1ts use. 
I 
Takac's biieved that thiocyanate exerted its hypotensive 
3ffect through a powerful stimulating effect on the vagus. 
~~stphal and Blum70 postulated that thiocyanate "increased the 
nlrmeability of the arterioles and decreased their tonus by t'",l 
I, 
14 
• I 
li 
decreasing the blood chole~terol". Pauli67, McNeill74, and 
. 
. Ayman32 have attributed a sedative action to thiocyanate. 
Griffiths75 proposed that the thiocyanates relieved muscular 
spasm because of an increase in cutaneous lymphatic flow after 
successful therapy in some pat~ents he observed. 
Although many hypotheses have been postulated concerning 
thiocyanate's mechanism of action, the definitive work still 
awaits completion. 
7. TOXICITY (See Charts V-A, V-B and V-C) 
In my review of pap~rs that referred to toxic manifestatiors 
of thiocyanate, I found that seventy-four different reactions 
1rere reported. In the accompanying tables I have followed the 
imethod outlined by Wald, Lindberg and Barker21 for classifying 
rhe toxic effects or the thiocyanates. There are three tables, 
liach divided into a pre-Barker and a post-Barker section. 
~very chart lists the author, the dosage used and places the 
~riter-in his respective pre or post-Barker niche. Chart "A" 
~eals with the severe manifestations of thiocyanate intoxieatioi ; 
~he second, chart B, with untoward effects that may be consi-
~ered mild or severe; and the third chart, chart "C", with the 
~ld toxic effects occurring within a safe therapeutic range. 
I 
A. SEVERE TOXIC MANIFESTATIONS (See Chart V-A) 
(a) Severe toxic psychosis 
I Severe toxic psychosis is the most dangerous of 
! 
toxic symptoms, for the majority of deaths incurre< 
f 
the 
as a result of thiocyanate toxicity are preceded by it 
15 
1 
l 
I 
[o. 
CHART V.-A i 
SEVERm TOXIG ;1AIU.E'ESTATIONS OF THIOCYANA'.JE IN TEE PI®-J3ARKElR AND POST ... BA.'RKHJR ERA 
PEE-BARBER ERA 11904 ... 1936) 
~UTHOR DOSAGE 
11 
II Nichols, B.J.l4 l ~· per day . 
Westphal, Ka*9 .3 ... 1 gm. daily 
r.1eakiAs, J $3 : ,6.-.a gms. daily Weis, \\O.R51 ,32 l bide A'Ylllan~ D. 25 .6 gms. daily Logef~el, R.o56 l gm. daily Tyrrel\1, J"~~ .2-.. 5 gms. daily 
.Borg, \p-.F. 29 3-l @:11• daily Eglo~~:' \1 •. C. 39 20 3-l gn, daily Goldring, w. ' 2-1.6 gms. daily Palmer~ R.S. 52 ' 51134 ;.3.-l @D.• daily 
J.A,M.A.l02;63740 12 gms. in 16 hrs. 
\\ l?OST.-BA.BKER ERA. (1936 ... 194G) 
l 1 1 l 
11 l 
1 
J 
] 
2 
1 
4 1 
l 
2 2 3 2 7 7 7 l 7 
1 5 
2 7 l 
l 
7 
Massie~ E. o. 47,42 . 5 ... 7 mgms. per 100 co. b.s. l 
Robins&n,. R.W. 79 6.-12 mgms. per 100 co. b.s. +-==1-1=--1--I-HH-t:::::.2+1=+-l-:-++-l-++--f2~l::...;.::1:..;-+-
GarvinJ11 G. F. a l 9 gms. in 12 days +-.J-J'-+-+-f--1-.{--if-+:. :..:1=-!--1-.J--.1H4-+4=l+-+--
Massie Jj E. o. 47,42 6.-12: mgns. )?er 100 oc. b. s. +=l:.l--1--.J.-hHH-t-+-l--+-+++++-+-+-t-1--
Hamburger, w. Vl. 7 l bid. l l 
tl 100 6 100 b 2 Flaxne11' M. 
46 
mgms. per co. .s .. 
Kurtz, 
1
0,r!. 6-12 mgms. per 100 co. b.s. -1-~-l-t-:J-,.I~-J.-=l+--1-.,..._l--lf-1~-+-+-+-+--+--1--
Plessetl~ M.:a 69 ? · l 
Barker,\\ H,!l, 4,;S22,12 8 ... 12 mgms. per 100 cc. b.s • ..t::~:::::.2.J-1H-t-++-+-+-HH-+-+-+..P:.lrl:...P?+-+-+--=4=-
Ru.ssell, \V.n. ? . 1 l 
Q.uatt1ebaum7 J. T. 
97 6.-12 mgns.. per 100 c c. b, s • .J-.J-IH--t--1-+-+-+-H-+-++-+-+-+-1-l.:::l+-i--Solomon~ J. a 6.-9 mgms. per 100 cc. b.s. 1 1 
Scherer 11 R. I a2 ? ~I 6B ? 
2?.1. 
Ode1, 1!.:
1
\H•. 94 Peterse:q, D~. Ko~~1er~\ A. •66 
\1eeks, R!. :0. 77 
Del Sol~lr. V .. 45 
8.-12 mgJn.s. par 100 cc. b. s • .&--1-1--ii-IH-t-+-++-1-++++-+-+-4-=t--1--t--1--
~ ~ 
? 
b.s. - blood serum 
Pre-Barker 
Post ... Barker 
cc. - oubic centimeters 
gn .... glfas .... gram - grams 
\\ ~ _ l~o :ention o:f level maintained 
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9 l ~ 3 7 '7 114 6 lQ l 12 
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It follows a fairly characteristic pattern, as D~l 
Solar45 points out. He summarizes its course in the 
following manner: "Often a high degree of asthenia 
precedes the onset of symptoms. Thes~ are initiated 
with dysarthria and sometimes verbal aphasia and are 
followed by mental dullness, clonic contractures of 
the extremities and a deliriant state with visual or 
auditory hallucinations, sometimes with a great mental 
and motor excitation. In fatal cases, despite the 
discontinuance of the drgg with theonset of symptoms 
there is a downhill course with accentuation of the 
mental confusion, convulsions, stuporous state, coma, 
sphincter incontinence, collapse and death three to 
nineteen days from the beginning of symptomsu. This 
clinical summary compares well with the experimental 
resUlts obtained by ~icholsl4, concerning the severe 
toxic effect of thiocyanate on guinea pigs and dogs, 
and Lindberg76 relating to the effect of poisoning 
over a long period of time on dogs. 
Eleven cases of death as a result of thiocyanate 
toxicity have been reviewed by Del Solar4'. He 
concluded that "by strict observations of the indica-
. 
tions for correct administration according to preva-
lent concepts, severe and fatal intoxications could 
be entirely avoided". His paper neglected to include 
two other reeent reports of death associated with 
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thiocyanate therapy reported by Weeks?? and sblomon78. 
Week's case was one of incompetent clinical manage-
ment. The case was brought to him in the toxic state 
without any record of therapy, not .to mention having 
a blood level determination. In Solomon's case death 
was not directly a resultant of thiocyanate therapy, 
I 
although it played a part. He states "it is difficult 
to evaluate the exact part played by the potassium 
thiocyanate, and indeed it is possible that several 
factors are operative, including the renal impairment, 
elevated potassium thiocyanate blood level and special 
tissue vulnerability". 
Other severe toxic manife~tations recorded, such 
as disorientati0n, halucinations, mental delusions, 
stupor, motor aphasia, convulsions, coma, visual un-
certainty and unsteady gait, all seem to be indica-
tions of, or a part of, the severe toxic psychosis 
syndrome and should serve as danger signals. 
(b') Exfoliative dermatitis 
Seven cases were recorded in the literature I 
reviewed. Weis describes it as "an acute, diffuse, 
erythematous dermatitisrr at its onset. It envolves 
the face~. neck, hands, forearms,· and spreads over 
the chest, shoulders and back without being delimited 
by any particular border. The eruption was preceded 
by itching and burning symptoms for two days. "It 
18 
''0 I' 
',I 
progressed rapidly and reached its maximum intensity 
at the end of four days", at which point Weis depicts 
it as being a "generalized, erythematous, papular, 
squamous eruption". Robinson79 states that "a month 
passed after discontinuance of the drug before the 
lesions were entirely healed''. 
(c) Angina 
Eighteen reports of angina or increase in anginal 
pain and three cases of precordial distress have been 
observed. 
Palmer and Sprauge34 reported two cases of angina 
and attributed them to the hypotension incurred by 
the thiocyanate and not to its toxic effect. Wald 
and Barker21, (CHART IV) studied 47 patients showing 
that thiocyanates were no more responsible ~or angina 
than in a group of patients treated by other means. 
"Nevertheless", Wald states, "we are certain in a few 
cases in the last group the angina has developed as a 
direct result of the hypotensive effect of the drug11 • 
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CH.ART IV 
THERAPEUTIC RESPONSES TO THIOCYANATE THERAPY AND TO O'JRER* 
Thiocyanate Other 
Thera;El Therapy Totals 
I TREATMENT Number-Percent Number Percent Number Percent 
INo history of pre-
vious pain (Groups 
1 and 3) 24 100 7 100 31 100 
!Pain developed while 
being observed 
I (Group 3) 3 12.5 1 14.3 4 12.9 
1
Complaint of pain 
1 before observation 
11 100 5 100 16 100 (Group 2) 
Pain relieved while 
· being observed 7 63 • .5 -4 so 11 68.7) 
Pain mitigated 1 9.1 0 0 1 6.2 
Pain questionably. 
relieved 1 9.1 0 0 1 6.2 
Pain unaffected 2 18.2 1 20 3 18.7 
*In people suffering from angina 
*All cases in which thioeyan~te was given at any time are 
included, w~r or not the level of blood thiocyanate 
was considered within the therapeutically {as regards 
blood pressure) effective range. In no case listed was 
blood thiocyanate ever displayed in the "toxic" range. 
Chart by Wald21 et al. 
On the other hand, Paul White101 in his paper on 
the medical treatment of angina pectoris recommends 
ttstrict rules of rest, exercise and diet" for the 
prevention of further attacks, which seem to be in 
accord with the medical procedure for the reduction 
of blood pressure. 
(d) Other severe toxic effects 
Other severe reactions that have been assigned 
to the toxic effect of thiocyanate by various authors 
20 
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have been as follows: One case of hemiplegia, one 
case of bronchopneumonia, one instance of myocardial 
failure, one case of pulmonary infarct, a subdural 
hematoma, one cardiovascular·accident, and four oases 
of thrombophlebitis. 
B. MILD OR SEVERE TOXIC MANlFESTATIONS (See Chart V-B) 
(a) Gastrointestinal disorders. 
Gastrointestinal upsets, consisting of general 
disc~mfort, gastroenteritis, anusea, diarrhea, vomitin~ 
and abdominal pain constitute the second most usual 
indication of thiocyanate toxicity. It is the most 
common one occurring outside of the safe therapeutic 
range. Wald21 states that "they do not occur within 
the usual therapeutic levels". 
The first gastrointestinal:disorder to be noted 
when the thiocyanate levels in the blood serum rise 
above the "usual therapeutic levels" are nausea and 
vomiting. Wald21 points out that "severe diarrhea, 
abdominal pain and cramping may occur independently 
or as a part of a general extreme toxic staten. 
Wald21 adds that some hypertensives suffer gastroin-
testinal symptoms as part of the hypertensive syndrome 
which will disappear with the reduction of blood 
pressure. Wald2l concludes that "if the blood level 
is within safe limits there is no need to fear thio-
cyanate poisoning". 
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(c) Dermatitis 
Other types of skin symptoms, aside from the very 
severe exfoliative kind, are the maculopapular and 
vesiculopapular dermatitis, iodotic rash, exanthema-
tous rash, acneiform rash, furunculosis and purpura. 
These skin manifestations soon disppear upon discon-
uance of the drug; but, if thiocyanate is unrecognized 
as the agent, serious consequences might result if the 
drug'is not stopped. 
(d) Goiter 
There have been twenty instances reported of hypo-
thyroidism occurring during the administration of thio~ 
cyanate. In every case relief has been obtained by 
ceasing the utilization of the drug or by some other 
measure. Rawson, Hertz and Meansao, (CHART VI), 
correlated experimental and clinical evidence to show 
that thiocyanate causes the goiter by blocking the 
formation of functional thyroid hormone. 
They describe thiocyanate goiter as follows: 
"Thiocyanate goiter is characterized by a) hyperplasia 
of the thyroid, b) symptoms of hypothyroid~sm, c) exo-
pthalmic goiter, d) low metabolic rate, e) low blood 
iodine, f) decreased urinary excretion of labeled 
iodine, g) increased urinary excretion of thyrotrotro-
pic hormone in the inactivated form, h) Idiosyncrasy-
sensitivity". 
I' 
·b 
' 
2 
\ 
3 
~ 
fllij 
, ',rT. c. 
\.(1-1. 
Diagrammatic representation of ~he effect of cyanate on t~~ 
pituitary-~id axis.* 
j-1 
• Normal relationships. The anterior pituitary•AP-by means of 
its hormone-TSH-and in the p~esence of a~ adequate supply of 
iodine, stimulates the thyroid-T-to produce its hormone-TH-
which stimulates the metabolism of tissue cells-TO-and inhibit 
.AP. 
I ~ 2·. Cyanate imposes an obstruction to the completion of TH. The 
I BMR of TC therefore falls, and the uninhibited AP produces an 
excess of TSH. This causes hyperplasia of T, but since the 
block remains, no active TH is delivered to the body. 
3· The supply of an excess of iodine forces the cyanate block so 
r that TH is made in adequate amounts, BMR remains normal and TS 
formation remains normal, and therefore no enlargement of T 
takes place. 
4. The supply of T.H from without by-passes the cyanate block so 
that BMR remains normal and TSH formation remains normal, as 
does th~ thyroid gland. 
*CHART FROM RAWSONBO 
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Ga • 81 . h" t f rv~n ~n 1s repor o a death due to thio-
cyanate therapy summarized his paper as follows: 
"This case presenting fatal manifestations of the 
thiocyanates is especially significant in that unto-
ward symptoms occurred while the blood cyanates were 
at the supposedly non-toxic level. Death was appar-
ently due to an idioayne~asy to the drug, and, since 
such intolerance can't be recognized in advance, thio-
cyanate therapy must be considered dangerous". 
Koffler86 recorded four oases of thrombophlebitis 
occurring as a result of thiocyanate therapy which 
he attributed to idiosyncrasy or sensiti~ity. Fahlund 
concluded that a painful swelling of the thyroid, 
associated with acute gastroenteritis and a diffuse 
maculopapular dermatitis, that he noted during treat-
ment with thiocyanate was a manifestation of sensitivi~y 
. 
to the drug. 
Odel88 reported three oases in which histamine 
was capable of relieving sy~ptoms of angina pectoris 
thought to be a resultant of sensitivity to thio-
cyanate ingestion. 
Nelsonl8 opposes those attributing certain unex-
plainable untoward reactions to thiocyanate in the 
following paragraph from his paper: "There has been 
some disposition to interpret the cases reported of 
untoward results occuring after relatively small 
2.5 
0 
0 
amounts, or at blood levels usually considered safe, 
as due to idiosyncrasy. I believe they are rather 
expressions of the fundamental fact that there is wide 
variation in quantative response to drugs or in the 
amounts necessary to give constant responses. If this1, 
be true, as experience grows, more and more toxic re-
actions of all degrees are to be anticipated and will 
be observed. -It thus becomes the responsibility of 
the individual physician to attempt to assay the 
risk of treatment with these admittedly toxic sub-
stances against the probable gain of the patient, a 
task not new for him." 
' 
C. MILD TOXIC REACTIONS (See Cha·rt V-C) 
General weakness, increased nervousness, drowsiness, 
lassitude, laziness, decreased libido, anorexia, muscular 
fatigue, etc., are fitted in this grou~. General weakness 
and fatigue are the most common an~ occur in seventy-five 
percent of the cases21. They disappear after four to six 
weeks of continued treatment and will not disappear before 
that time unless therapy is discontinued. Some of the 
fatigue, muscular aches and cramps, may be due to the 
hypotension and the reduced circulation, for if the drug 
is discontinued the patient feels better as his blood 
pressure rises to its former 1eve1. 21 
Many authors have reported on the increased nervous-
ness and irritability noted by patients while taking 
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r!to. .AUTHOR DOSAGE >· Nichols/~ B.J\~4 l gm. daily tL 
1'2. -~7estphai~, K00 .3 ... 1 gm. daily B tL 
I! 3. Gager, f•T• 24 .1 .... 3 gms. daily 
[]._ 
,4. Smith, ~G. 25 .33-1 gm. daily 4: 1 iS 
!' 5. Logefi~~' 3lf• ~ 1 gm. daily 3 9 s 
'
1 6
• Ayinan, jf• '52 51 34 • 3-1 gm. daily 5 7 8 !1.7 
::7. Palmer,
1 
R.S. 29 ' .3-1 @11• daily l s tL 
j.' a. r.ragu.ir~1 , L~l· .1-.3 gms. daily 1 l 
,: 9. Borg, JFF• 35 .3-l @11. daily 1 8 iO. Fineber,g, 1.1.~ l-.3 gm. daily ? ? 
,, If 
.3-1 gm. daily lf!J. ;~1. Eglof£'J1 We 0. 39 20 1~2. Goldring, W. 30 .2-1.6 gms. d~ily ~ !0,.3. Bolot irl, TI. T. 1.3 gms. daily 5 
I II I I 
: I' POST~BABKER ERA. (1936 ~ 1946} 
II 1m. UassiaJ E. 47,42 5-12 mgms. ]?e~ 100 co. b.s. ~ 
16. Bynum~ ll\7• T. 44 Ibid 3 p 
17. Robinson, R.C. 79 8.-12mgms. per 100 oo. b.s. 2 ~ 
18. Flexne~, m. lOO not 8 mgms. per 100 oc. b.s. p 
19. Blaney~ L.F.99 8-15 mgms. per 100 oc. b. s. f1: ~ 
20. Freemah I. 98 7-15 mgms. per 100 oo. b.s. 12 II t 
21. Griffijth, J.Q.Jr.75 8.-11 mgms." per 100 ca. b.s. I? I? 19 
"' 22. Barker;~ H.:n. 46,2297 8-12 mgms. per 100 oo. b.s. 1 r.> 23. t}.uattlr baum, J'. T. 55 8-12 mgms. per 100 oo. b.s. 12 24. Tuckerriller, 9~.A. ? 25. Russel~, U.D. ? lk 94 8-12 mgms. per 100 oo. b.s. 1 fg:. tl: 21il. _:Peters,/ n, ~J·i• 
2'()rotte,l H. 82 8.-12 mgms. per 100 cc. b.s. 
l 'rl ~ 
28. Schara~, R.L. 83 ? 
1 4 15_ ~-
29. D'Sil~~' J.L. 4-ll mgms. per 100 co. b.s. 2 1 
:PRID-BARKER 3 l l 3 7 5 7 4 9 l5f 1!3 
POST BARimR tL 1 7 l 3 ? 6 2 4 8 32~ 
... 
:.Q 
I• 
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thiocyanate25., 29, 45. Others have emphasized its sedative 
effects67,74,32• Wald21 feels that if the thiocyanate is 
in the therapeutic range that these symptoms are not contre~ 
indications. 
8. PREPARATIONS AVAILABLE 
Thiocyanate is dispensed in both liquid and tablet form. 
The "National Formularyu102 , a publication of the American 
Pharmaceutical Association, contains a formula for the prepara-
. . . 
tion of Elixir Sodii Thiooyanatis. Its drug content is .16 gms~ 
in 4 co. The Parke-Davis product contains 1.5 gms. in 30 co. 
Eli Lilly produces enteric coated tablets. Their advan-
tage is purported to be; firstly, standardization of dosage 
. . 
is assured and, secondly, the disconcerting gastrointestinal 
symptoms are av.oided. 
No mention of the drug is found in "New and Nonofficial 
Remedies", a publication of the Council on Pharmacy and 
Chemistry of the American Medical Association; for its ~hera-
. . 
peutic value has never been recognized by this organization. 
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TBERAPEUTICS 
"No remedy can or will reduce the blood :pressure so kindly or 
quickly, when given after a :proper manner, as the thiocyanates" 
Le Roy-190.5 
1. HISTORY OF THIOCYANATE'S THERAPEUTIC USE 
The statement made by LeRoy in 190.5 has been the subject 
of a great deal of discussion. It has been condemmed by many 
subsequent authors and reaffirmed by others, however, with 
much more qualification, in the light of :present knowledge. 
The earliest experiments with the sulfocyanates in respect 
to their hypotensive effect are attributable to Pauli67 in 
1903, who assigned a sedative quality and an ability to lower 
blood ~ressure to them. He reported two series of cases, 
exhibiting arterial hypertension, which he treated with thio-
cyanate. In his first103 , 3.5 clinical cases, he observed that 
the drug exerted a very satisfactory sedative effect on the 
pain, vertigo, restlessness, insommia, irritability, fear, 
:palpitation, increased reflexes, tremors, etc., of neurasthenic 
conditions, cardiac neuroses, tabetic pain, syphilitic head-
aches, and like conditions. In another group he obtained 
marked reduction of blood pressure with relief of vertigo67, 
and other subjective symptoms. He found various analogies 
between the action of iodides and sulphocyanates, even as to 
the occurence of a sulphocyanate rhinitis and acne. Because 
of this relationship and the property of iodides to aid the 
elimination of earthy salts, he suggested that the ~~l:pful 
action of iodides and sul:phocyanates in arteriosclerosis may 
29 
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be due to their pow~r to remove calcareous deposits in arteria~. 
In America, LeRoy and Bently68 , in 1908-1909, proclaimed 
that the sulphocyanates exerted a solvent and eliminative 
effect on earthly salts, which could be counteracted by am-
monia. Upon this basis they recommended the use of sulfocyan-
ates in the elimination of calcareous and similar deposits in 
various degenerative conditions. They also reported success 
with sulphocyanate in the treatment of hypertension. 
Interest in the use of these drugs for the relief of high 
blood pressure lagged after these initial experiences until 
about twenty years later, when two papers dealing with its use 
in the treatment of hypertension were published almost simul-
taneously, one in Germany and the other in America. 
In this country an article by Nichols14 reviewed the 
pharmacology of the sulphocyanates, adding his own personal 
clinical and experimental results. Nichols14 states that his 
experiences did not support Pauli's contention that s.ulpho-
cyanates had a marked sedative effect. He observed that a 
considerable portion of the patients had disagreeable effects 
from the use of the drug necessitating a reduction of dosage 
or discontinuance of therapy. These symptoms did not appear 
until the drug had been taken for some time; therefore, he 
concluded that the toxic effects might be a result of accumu-
lation of the drug in the system. He advocated its use never-
theless, stating "it was the most etfacacious remedy available 
i for the treatment of arterial hypertension". 
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The German investigat~ons conducted by Westphal and 
colleagues relating to the use of rhodan compounds also yielded 
favorable results. Westphal49 preferred smaller dosages of 
the drug for he noted that larger doses yielded e~mptoms of 
intoxication and were inflammatory in nature with agitation 
and delerium resembling psychosis and great muscular weakness 
and fatigue. Although the smaller doses did not reduce the 
pressure appreciably, Westphal felt it prevented fluctuation 
of the pressure, to which he referred the cause of apoplexy 
and many of the complaints uttered by hypertensives. Westphal 
noted that the use of rhodan was contraindicated in those 
patients with severe kidney disease, serious cardiae decompen-
sation or any inflammatory condition such as pneumonia; bron-
chitis, tuberculosis, eto. He believ.ed it increased the danger 
of intoxication in the patients having these afflictions. 
Westphal was of the opinion that sulphooyana~e therapy met 
with more success in the leviation of hypertension than other 
drugs, e.g., nitrates, bromides, compounds of calcium, iodine, 
endocrine preparations, eto. 
Kramer1°5 in 1~25 reported favorable results and no unto-
ward reactions in the long continued use of rhodan for the 
treatment of high blood pressure in seventy cases. T.he contra· 
indications noted in his studies were comparable to those 
found by Westphal4~. 
Gager50, (1~28), found that therapy was uniformly satis-
factory if the patient cooperated fully and his physical 
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obstacles were not too great to overcome. He suggested that 
confirmation and further investigation of the effects of thio-
cyanate were indicated. Another encouraging study by Rudolph 
and Smith
24
·at about this time stimulated more clinical probin! 
by others. 
Early in 1929 Logefie125 published a paper in which an 
organized study of the patient, that he deemed necessary 
before therapy with thiocyanate began, was outlined. T.his 
\\enabled the investigator to determine; first of all, whether 
!!the patient was a suitable candidate for thiocyanate therapy ar d ~econdly, it made interpretation of success much more accurate, 
~ogefie125 observed that thiocyanate therapy produced satis-
]\ 
factory results. Shortly following his study, Palmer, Silver 
lnd White51 reported that thiocyanate deserved a clinical 
lrial and that further work was contemplated. After further 
Jtudy they52 concluded that the hypotensive action was not 
llsting and was effected in but ~l~ of the cases. Just previou·S 
Jb Palmer's paper51 in 1929, the Council of Pharmacy and Chem-
iltry of the 4merican Medical Association discouraged the use 
1\ wa 
oT thiocyanate in a J.A.M.A. report • , 
I' 
\
1 
Between the first51 and second52 of Palmer's reports, five 
wlll controlled studies, 26• ~5 •~1 • 29 •20 recorded definite fail-
ules and five other pa:pers,33,36,38,39,5l made investigators ! ,. the t,;;ic manifestatioll5. Ayman107 emphasized the ~r.a~e c~ 
i • ~aluating blood pressure changes in hyperten-
1. :r ~ultY jll '/ • 
.32 
' ~lt ~ r the extreme variability with each pat~ent ~i~es becaus_e~;·============================~==============ir======~ 
II =· 
throughout the day depending on the person's emotional state 
108 
and environment. He demonstrated clearly that symptomatic 
c:) r~!ief could be obtained by the suggestive elements inherent 
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in any enthusiastically prescribed drug or therapy. T.his 
prompted clinicians to take cognizance of the fact that careful 
study and control of the patient was necessary before results 
could be significant. In 19323° Bolotin warned physicians of 
the contraindications to thiocyanate therapy and listed specifjc 
, ones. 
After 1933, because of numerous dissuading statements as 
~~ to thiocyanate's impracticability and toxicity, few studies 
\were undertaken. However, the situation changed following II 
~Barkerts22 announcement in 19.36 of a method of controlling 
\blood levels of thiocyanate by concentration determinations 
I 
\made with blood serum. Barker's enlightening results prompted 
1
rther workers to try thiocyanate again with the new control 
coupled with the method of studying the patient that had 
bvolved through the years. Although there have been many re-
torts of toxicity of all variety and degree, (See Chart V), 
!he majority of investigators today feel. as Del Solar45, (1945 
!oes "that by strict observance of the indications for correct 
Jdministration according to prevalent concepts, serious and 
Jatal intoxications could be entirely avoided". He45 advocat~f. 
·Jkeating only patients for which thiocyanate therapy is indi-
11 
oated ahat respond to blood levels of 2-5 mgms. per lOO;cc. 
I 
studies published since 1936 all convey the impre :z;ne nWile.rous 
I 
\ 
.33 
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ssion that thiocyanate is worthy of trial except papers 
recently released by Goldring8, Kotte95, and a report in the 
J.A.M.A. (1940). 
T.he J.A.M.A. 109 made the following statement based on 
Garvin81 and Hamiltonts110 experiences with the drug: "in 
view of recent reports the use of thiocyanate seems even more 
dubious because of its dangerous effects". 
Goldring20 bases his attitude on the use of thiocyanate 
in the treatment of hypertension on his exhaustive study of 
the drug in 1932. He has not tried the new method of control 
advocated by Barker22 , that is to say he hasn't written a 
pape'-1" :making his findings known, because he feels that his 
own technique ~f thiocyanate control, by determing the residua 
drug in the body after subtracting the amount of urinary thio-
cyanate exc~etion, was a valid enough one. In his clinical 
trial on seven patients he found that there was little or no 
correlation between the amount of residual drug and the onset 
of toxic symptoms. He concluded, as a result of this study 
and the rest of his investigation, that the relation between 
the toxic and therapeutic dose was too small to make thio-
cyanate a practical mode of treatment. In 19438 he reviewed 
his old work and reiterated his previous dictum as follows: 
"We are of the opinion, therefore, that thiocyanate should not 
be administered to hype~tensive patients for the purpose of 
lowering blood pressure, because apart from its toxic effects 
its influence is not striking in either the frequency or the 
34 
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extent of the blood pressure reduction, that almost any medica 
or psychosomatic measure may be expected to yield results 
equally effective and with no element of danger". 
Kotte9.5 states that "until more is known about the mode 
of action of this drug it cannot be recommended for general 
use in the treatment of hypertension". 
This brings us up to date in respect to thiocyanate's 
oscillating therapeutic history in the mitigation of hyper-
tension. What the future holds for thiocyanate in this field 
cannot be foretold. 
2. RATIONALE 
T.he early workers used thiocyanate because it had been 
shown to be capable of lowering elevated blood pressures in 
humans. As a result of clinical and experimental studies since 
that time, several concepts as to its mode of action Rave been 
built on plausable physiological grounds. The three most 
acceptable hypotheses are those of Barker and Davis, Caviness 
and Friend and Robinson discuss~d under the pharmacological 
aspect of thiocyanate. None of these postulates have been 
unequivocally established; however, each seems to have consi-
derable merit. One m;ght infer that probably more than one 
factor is at work to achieve the end result obtained. 
3. TREATMENT 
A. Selection of Patient 
Some of the earliest workers reported that the pat-
ients they used thiocyanate on were unselected hypertensives. 
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Undoubtedly their-reason for doing this was to determine 
which type of hypertension thiocyanate was most effective 
for. T.he experiences of others in the past have shown 
the clinicians of the present that c,areful selection of 
the patient is one of the most important phases of succes~­
ful treatment with a drug that has dangerous.potentialities. 
The patient must be cooperative, for it behooves 
him to be prompt enough to return at the proper times for 
blood level determinations, blood pressure readings, etc., 
and intelligent enough to do what is prescribed. A case 
of severe toxicity has been reported in which the patient 
had taken double the dose thinking he would get well twice 
as fast. It is the attending physician's responsibility 
to explain adequately the dosage and the necessity far 
frequent revisits to the patients' satisfaction. 
The indications tor therapy employed by Barker and 
W~ld12 are: "First, when other clinical measures have 
failed (social and psychiatric adjustments, sedation and 
prolonged rest, cardiovascular support, vasodilators and 
the like); second, when the patient's condition is either 
uncontrolled by the measures just mentioned for excessive 
sedation is necessary to control his symptoms so that he 
is physically, mantally and socially incompetent to carry 
on his daily routine; finally, after surgical treatment 
has been unsuccessful". He lists no contraindications 
in any of his work. Doles60,6l, of course, would include 
0 
as indications all cases of hypertension that were a 
result of hyperchromic macrocytic anemia. Griffith, Jr.?! 
believes a hypertensive with normal capillary count and 
minute vessel pressure reaction, are good candidates for 
thiocyanate therapy. Freeman98 has proposed the ide~ 
that thiocyanate should be indicated for young, asympto-
matic, hypertensive people to ward off chronic vascular 
disease. More study of this co~sideration is warranted. 
Wald and Earker21 report the following: "Several elderly 
patients with severe grades of prog~essive vascular 
disease with hypertension, who were at first plethoric anc 
obese and had good muscular development were placed on 
cyanate therapy. Today, after five to ten years of con-
stant and vigorous treatment with satisfactory blood 
pressure readings, they present a picture of anemia, ema-
ciation and muscular wasting. T.hey are constantly fatigue~ 
and have no ambition". Is this a toxic reaction resultin~ 
from long, slow, continued poisoning, or a result of the 
progressive vascular disease with those who would have 
died of heart failure or a cerebral or coronary acaident 
many years earlier except for thiocyanate and its hypo-
tensive effect? Wald21 states "Younger patients do not 
show this effect". It has been shown that tuberculosis 
' 
and digitalis are not contraindications to therapy with 
thiocyanate111• 
T.he first list of contraindications compiled was 
37 
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quite long and impressive3°. It was drawn up in the pre-
Barker era. Since the blood control has been instituted, 
some authors44 'S?,?? consider few or no oontraindioations 
to thfuooyanate therapy. Massie42 makes the following 
qualifications: "~iooyanate therapy, generally speaking, 
should be restricted to oases of uncomplicated vascular 
hypertension in patients not over sixty years of age. 
Patients should have satisfactory cardiac function or at 
least no evidence of angina pectoris or cardiac decompen-
sation. Renal studies should show fairly nor.mal kidneys; 
at least the non~protein-nitrogen should ge within normal 
limits. Preferably there should be no history or physical 
signs of a cerebral vascular accident in the recent past"• 
On the other hand three reports26 , 43,99 state that sex, 
age, duration of hypertension, grade of hypertension, de-
gree of cardiac and renal envolvement and the.degree of 
vascular envolvement showed no positive correlation betwee·~ 
the degree of any of the factors and the therapeutic 
results. D'Silva83 reports poor response in oases of 
active arteriosclerosis as evidenced by active hematuria 
113 .d 
and retinal changes. Ayman and Mandelbaum cons~ er 
cardiac and renal impairment oontraindioations. Robinson 
and otHare79 consider any severe athero or arteriosolerosi~, 
renal disease, congestive heart failure, angina pectoris, 
cerebral accident or mental disturbance contraindications 
to therapy. 
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All these woxkers have been satisfied with their 
results from thiocyanate therapy, so~t is difficult to 
choose which criterion is the proper one, if any one is. 
One should certainly be aware of all the factors mentione< 
before geginning therapy with the drug. 
B. Procedure of Treatment 
After reading many clinical reports, I find, that 
although in general investigators proceed along the same 
line, every clincian varies a bit, either as to the ex-
tent of the pre-therapeutic work-up, length of control 
period, length of treatment, post-therapeutic follow-up, 
etc. Therefore, I will try to outline a procedure, con-
stituting a composite of the plans employed in several 
investigative studies that will include all the elements 
that seem necessary for an adequate clinical work-up 
before conducting therapy with thiocyanate. 
A patient who is found to have hypertens·ion and 
associated findings should be completely studied to deter-
mine the etiology of the s~ptom complex in order to 
evaluate the proper treatment. If there is no specific 
treatment, e.g. antileuetic or liver extract, if general 
medical therapy fails and surgery is not indicated, then 
thiocyanate shou1d be oonsidered. 
Before initiating thiocyanate therapy the patient's 
history, physical examination and laboratory reports 
should be evaluated with thiocyanate therapy in mind, 
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being aware of all the factors mentioned in the previous 
section concerning the selection of.the patient. A 
complete history should be elicited. In the physical 
. 
examination special attention should be directed toward 
any cardiac abnormality, opthalmoscopie pathology and 
the height and variability of the blood pressure. Labor-
atory work should include and electrocardi.ogram, an x-ray 
of the heart, urinalysis, dilution-concentration test 
(i.v. pyelogram and flat plate of the kidn~y, if necessar }, 
white blood count, hemoglobin, hematocrit and non-protein 
nitrogen determination· (blood urea-nitrogen and creat-
inine level, if indicated). 
It would clarify the clinical results of carefully 
followed cases, if as Fanson13 has done, the hypertensive 
patients were graded (I,II,III,IV) according to the heigh 
and variability of the blood pressure, degree of opthal-
moscopic, renal and cardiac envolvement. 
A control period of two mqnths to one year must be 
undertaken next. During this time the patient must be 
required to rest, eat properly and be subjected to seda-
tive therapy, if necessary, so that the blood pressure 
for the patient can be stabilized at a r.elatively constan 
value. Blood pressure readings114 (proper method out-
lined) should be taken at weekly or biweekly intervals 
accompanied by questioning about symptomology and the 
acquirement of a urine specimen. 
40 
~ 
~ 
~ 
~ 
~ 
;:::'_ 
I 
~- I 
II '-t 
p 
.,. 
l:v 
I t 
,l 
1l 
II 
11 
11 
I 
I 
l 
l 
I 
l 
' 
r 
I 
,! 1! 
:1 
,. 
I 
:I 
I 
I 
'I 
ll 
I 
I 
I 
I 
i 
' 
11 
;1 
.I, 
.. 
'I j 
'I 
After the control period of study, an interval of 
active therapy lasting for from three to six months 
follows starting with ., gms. daily, preferably in the 
enteric capsule form. ~e patient should be required to 
retunn in one week, at which time a blood serum concentra 
tion determination, a blood pressure reading and a urine 
speciman should be taken along with an interrogation and 
interpretation of the patient's symptomatology. Dosage 
should be varied ~s indicated (see "Dosage and Technique 
of Administration" in the section on pharmacology) to 
maintain a level preferably below 9 mgms. per 100 cc. of 
blood serum. The patient should be seen weekly, followi~ 
the same procedure in the same order, until his blood 
level is established at a therapeutically effective and 
non-toxic level. Throughout the therapeutic period, 
' following the establishment of a level, the patient shoulc 
be seen t~every two weeks or at least monthly, eaQli visit 
requiring the patient to undergo the procedure outlined. 
If the blood level at the end of three months has been 
established below 9 mgms. per 100 cc. of blood serum 
without untoward symptoms, yet no hypotensive effect has 
occurred, the dosage might be increased to maintain a 
level of no greater than 12 mgms. per-cent and the study 
extended for three months longer. However, if a hypo-
tensive effect has been observed at the termination of 
the three month period, with relief of symptoms, a blood 
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level below 9 mgms. percent and no untoward reactions, 
then the next phase of the study should begin. 
A placebo should be substituted for the thiocyanate 
capsule for a duration of three months, observing the 
effect on blood pressure and symptomology, with no change 
whatsoever in routine, including the blood level deter-
minations. The following determinations should be made: 
1. The length of time necessary to clear the bloodstream 
of thiocyanate; 2. Thepromptness with which the blood 
pressure rises and the extent to.which it rises; 3. The 
haste with which the symptoms relieved return and the 
severity of them as compared to those previous to treat-
ment. 
At the termination of this second control period 
active therapy should begin again for three months, with-
out any deviation from the routine established. The 
effects should be carefully observed and compared· to thos 
obtained in the second control period. If, during the 
first active therapy session, a reduction of blood pres-
sure with relief of symptomatology without toxic manifest 
ations was observed followed by'a return of all previous 
complaints and high blood pressure during the second 
control period, and then, during the second active pherap 
' interval, a relief of the signs and symptoms complained 
of occurs again, just as in the first, we might infer 
that therapy has been successful and continue it. If 
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therapy has not been successful, according to these 
s·trenuaus standards, treatment with this drug· is not re-
commended. An adequate study, therefore, lasts at most, 
1 
twenty-nine months and at least 10 months. 
c. Treatment of Untoward Reactions 
I Immediate discontinuance is in order whenever any 
"severe" or "mild or severe" toxic manifestations become J 
I 
evident, except for gastrointestinal upsets, in which 
1
j 
case Wald21 states 11if the blood level is within safe !! 
limits there is no reason to fear thiocyanate poisoning"~~ 
The majority of "mild" toxic reactions disappear 
in four to six weeks21 ; so there aren't any indications 
for discontinuation of therapy in these instances. 
Motley84 suggests that thiocyanate goiter can be 
I 
I 
~ 
r 
I 
I 
controlled in one of two ways. nThe wise procedure is·JD [I 
control the hypothyroidism with thyroid hormone during r: 
potassium sulphocyanate therapy, but in a patient sus-
pected of goiter give prophylactic iodine". 
Odel88 demonstrated that skin rash and the pain of 
I 
angina resulting 
therapy could be 
as noxious manifestations of thiocyanate[ 
controlled by desensitization with j 
histamine in three individual cases. 
Therapy can be commenced again after the untoward 
reaction has subsided. If it appears once more, that 
establishes it as definitely due to the drug and should 
be sufficient evidence to discourage further attempts 
'I 1 
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to treat that particular patient in this manner. 
RESULTS OF TREATMENT 
A. Interpretation of Clinical Results 
a) Normal blood pressure levels • 
Robinson and Brucer118 in their survey of nor.mal 
blood pressure in a statistical and clinical study 
of 11,383 eases concluded; firstly, that the blood 
pressure normal range, as acce~ted by the majority 
of men at present (140/90 mm. mercury upper limit) 
is much too high and their studies support the fact 
that 120/80 mm. of mercury, as an upper limit, would 
be more reasonable figure and more in keeping with a 
low mortality rate; secondly, blood pressure is 
constant from adolescence on with some change maybe 
at twenty-one; and lastly, persons with systolic 
pressures greater than 120 mm. of mercury tend to 
vary more than persons with pressures less than 120 
mm. ·of mereury. 
b) Interpretation of hypotensive effect. 
Ayman, n.107 points out that the sources that 
cause fallacies in the interpretations of hypotensive 
effects in the treatne nt of essential hypertension 
are two: 1. The lability of the blood pressure, 2. 
The 
of 
of 
hypertensive personality. In regard to lability 
blood pressure Ayman107 states, "the instabil:ity 
the blood pressure in essential hypertension will 
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often lead to normal readings o~ the blood pressure 
if the patient sits quiet from five to t~enty minutes~ 
This occurs even in patients with wide-spread vascular 
change". Pertaining to the hypertensive personality, 
Ayman
107 says "In general the hypertensive patient 
seems to have the same type of reactions as a person 
with nor.mal pressure but the reactions are greater 
in degree. Whereas the blood pres~ure of a normal 
person may rise to from 10 to 30 mm. of mercury 
during excitement, that of the hypertensive person 
more often rises from 30 to 100 mm. of mercury. · 
Similarly when mentally ar ease, the blood pressure 
of the hypertensive patient will fall much more than 
that of the person with nor.mal blood pressure". 
Therefore, an adequate study of the blood pressure 
under ideal conditions over a lengthy period of time 
must be undertaken to be able to substantiate a claim 
that there has been a fall in blood pressure or to 
determine what a person's average blood pressure is 
before beginning a specific therapy like the one 
being discussed. 
Ayman, n.108 states that the fallacies commonly 
encountered that lead to misinterpretation of olinica 
results in therapy are: 1. Absence of rest periods 
· when determining the average pressure before special 
therapy begins, 2. Insufficient frequency of visits 
during contro1 periods, 3· Inadequate length of 
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pretreatment observations. He encourages more 
careful studies of controls and stresses the impor-
tance of equating the conditions during a control 
period to those during active treatment. 
The minimal drop of blood pressure that may: 
be evaluated according to Ayman, D.lo8, is a persis-
tent drmp of 30 mm. systolic in an otherwise well-
controlled study, thus allowing a leeway for the 
effect of uncontrollable factors. 
c) Interpretation of symptomatic relief. 
Ayman, n. 117 observed, after treating a series 
-
of forty unseleoted hypertensive p~tients seriously 
and enthusiastically by the daily administration of 
a few drops of dilute hydrochlo-ric acid, that the 
symptoms were definitely improved in B21o of the oases 
Equating conditions during an adequate control period 
with that of an adequate therapeutic period, will 
eliminate false interpretations from this source. 
B. Experimental Results 
The experimental results obtained from treating 
animals (dogs in most oases) with thiocyanate have not 
been conclusive. Davis and Barker64 observed that there 
was an immediate drop of the mean arterial blood pressure 
in artifidally produced hypertensive dogs in addition to 
a reduction of the total serum protein, blood cholesterol 
and hematocrit reading. This duplicates the findings they 
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reported in man72. 
On ~he other hand, Hamilton et a1.110 noted that 
blood pressure values in street dogs with hypertension 
were effected by thiocyanate. They warned investigators 
about the seasonal variation in the normal dog's blood 
pressure in an attempt to help them avoid misinterpretatio·. 
In winter the pressure increased and as summer draws on 
it diminishes. 
Collins, Lansbury and Oppenheimer115 ebserved that 
no significant fall could be produced in hypertensive 
dogs maintained on therapeutic levels (8-12 mgms. per 100 
cc. of blood serum); however, falls in some instances coul< 
be obtained if doses ranging from 15-35 mgms per cent were 
administers~. These dosages were associated in all ~ases 
with severe toxic effects. Groililman et a1117 reported the 
same results in artificially produced hypertensive rats. 
47 
He stated that clinical men obtained their good results 
because of the variability inherent in essential hypertens on. 
_Goldblatt and associates119 recently found that the 
doses necessary to lower blood pressure in their dogs were 
very near the toxic levels. 
Hamilton 110 recommended further studies and Collin's 
contributionll5 was just a preliminary one; consequently 
• 
. 
more definite work can be anticipated in the near future • 
c. Clinical Results 
In order to report the clinical experiences of inves-
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tigators as regards the use of thiocyanate in the reme-
diation of hypertension, I have compiled Chart VII. 
it one can seen the variations that exist in the pro-
The 
I 
I 
! 
I 
r 
I 
cedures followed· by dif~erent individual workers. 
use of these numerous varying criteria employed in evalua~ 
ting the clinical results of thiocyanate therapy account ~ 
in part for the inconsistency of the results obtained by 
different physicians. 
The chart shows that the majority of reports found 
thiocyanate to be satisfactory in the pre-Barker eDa; and 
even more so, since thiocyanate blood levels could be 
trolled by blood serum concentration determinations. 
Although the evaluation of hypotensive effect is an 
evasive entity, the maj_ority of resea.t>chers agree that 
thiocyanate is 
criteria used. Th~ocyanate seems adequate also in its 
ability ~o relieve symptomatic distr~ss. Fanson13 states 
that "the commonest symptom and the one most effectively 
relieved was headache, usually hemicrania of the migraine 
type. Other subjective symptoms relieved were lighthead-
edness, dizziness and faintness, such re!ief being accom-
panied by an improvement in well~ being". BynUm.44 found 
that it relieved nervousness in some of his hypertensives 
treated with thiocyanate. 
The drawbacks to thiocyanate's. use are its noxious 
effects and the uncertainty that exists in regard to its 
fl 
:r 
d 
il 
.50 
mechanism ot action. In our discussion of the pharmaco-
logy of thiocyanate its toxicity has been reviewed and 
the postulates concerning thiocyanate's mode of action 
have been related. Nevertheless the majority of authors 
seem to agree that the results obtained justify the unto-
ward effects, if they occur, as evidenced by their 
favorable response to its use. 
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EVALUATION 
Clinical reports emphasize that thiocyanate is, by 
far, not the ideal remedy for treatment of hypertension, chiefl~ 
because of its untoward effects and the uncertainty of its 
mechanism of action. However, until other methods are perfec-
ted, and research is flourishing, that are capable of reduct ng 
the pressure and alleviating the disturbing sj.mptoms of the 
disease having an elevated blood pressure as its clinical 
sign, on a firmer physiologicall basis with fewer untoward 
reactions, the majority of workers that have studied the effi-
caer of thiocyanate in the medical treatment of hypertension 
express the opinion that, in cas.es where no other therapy has 
been successful, thiocyanate should be given a carefully con-
ducted trial with a properly selected ,Ia tient. 
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